Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.

doi:10.1158/2159-8290.CD-21-0910

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.

Cancer discovery - 1 Apr 2022

Biswas Anup Kumar, Han Seoyoung, Tai Yifan, Ma Wanchao, Coker Courtney, Quinn S Aidan, Shakri Ahmad Rushdi, Zhong Timothy James, Scholze Hanna, Lagos Galina G, Mela Angeliki, Manova-Todorova Katia, de Stanchina Elisa, Ferrando Adolfo A, Mendelsohn Cathy, Canoll Peter, Yu Helena A, Paik Paul K, Saqi Anjali, Shu Catherine A, Kris Mark G, Massague Joan, Acharyya Swarnali

Abstract excerpt

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has significantly prolonged progression-free survival (PFS) in patients with EGFR-mutant lung cancer, including those with brain metastases. However, despite striking initial responses, osimertinib-treated patients eventually develop lethal metastatic relapse, often to the brain. Although osimertinib-refractory brain relapse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehyde Dehydrogenase 1 Family

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Retinal Dehydrogenase

Share to Tretinoin

Source

Open in PubMed Open full text

Identifiers

PMID: 35078784
DOI: 10.1158/2159-8290.CD-21-0910
PMCID: PMC8983473

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.PMID 35078784Read ↗

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer.Semantic proximity Read ↗

Mesenchymal Transition as a Potential Mechanism of Late Immune Evasion in Neuroblastoma: A Case of Late Relapse after Allogeneic Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.Semantic proximity Read ↗

Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.Semantic proximity Read ↗

Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1Semantic proximity Read ↗

A Wnt/β-catenin signaling inhibitor, IMU1003, suppresses the emergence of osimertinib-resistant colonies from gefitinib-resistant non-small cell lung cancer cells.Semantic proximity Read ↗

Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.Semantic proximity Read ↗

All-trans retinoic acid induces durable tumor immunity in IDH-mutant gliomas by rescuing transcriptional repression of the CRBP1-retinoic acid axisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.